Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T06:33:28.825Z Has data issue: false hasContentIssue false
  • English
  • Français

Co-morbid Psychiatric Symptoms Influencing the Metabolic Syndrome in Patients Treated with Long Acting Injectable Antipsychotics

Published online by Cambridge University Press:  15 April 2020

L. Dehelean ,
A.M. Draghici  and
I. Papava
L. Dehelean
Affiliation:
Neuroscience /Psychiatry, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
A.M. Draghici
Affiliation:
Neuroscience /Psychiatry, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
I. Papava
Affiliation:
Neuroscience /Psychiatry, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

In patients receiving long acting injectable (LAI) antipsychotics, the risk of medication side effects needs serious attention.

Objectives

The study objective is to determine in which measure co-morbid psychiatric symptoms influence the presence of the metabolic syndrome (MS).

Aims

Patients receiving LAI antipsychotics have a history of medication non-adherence, with recurrences and partial remissions. The aim of the study is to assess the contribution of residual psychiatric symptoms in the development of the MS in these patients.

Methods

The study includes two samples of psychotic remitted subjects, one including patients on olanzapine LAI and the other one patients receiving risperidone LAI for at least six months. The presence of co-morbid symptoms was assessed with BPRS. The International Federation of Diabetes diagnostic criteria for the MS were used. The following information was analyzed: medication, gender, fasting glycemia, lipid profile, waist circumference, blood pressure, and psychiatric symptoms.

Results

The study included 28 patients, 15 (53.6%) on olanzapine LAI, and 13 (46.4%) on risperidone LAI. 15 patients were women and 13 men. 11 (39.2%) patients were diagnosed with MS. The whole sample presented higher scores at the following BPRS items: anxiety, somatic concern, and motor retardation.

Conclusions

Symptoms such as anxiety, somatic concern, and motor retardation may contribute to the development of the MS. 39% of the subjects presented the criteria of the MS.

Type
Article: 1602
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.